Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · Real-Time Price · USD
40.45
-1.50 (-3.58%)
Sep 18, 2026, 4:00 PM EDT - Market closed
Rapport Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 63.61 | 52.65 | 56.81 | 70.17 | 31.16 |
Short-Term Investments | 372.47 | 437.89 | 248.48 | 77.31 | - |
Cash & Short-Term Investments | 436.08 | 490.54 | 305.28 | 147.48 | 31.16 |
Cash Growth | 67.43% | 60.69% | 107.00% | 373.31% | - |
Prepaid Expenses | 10.28 | 7.82 | 4.42 | 1.5 | 0.11 |
Restricted Cash | 0.11 | 0.11 | 0.11 | 0.09 | - |
Other Current Assets | 0.1 | 0.1 | - | 1.81 | - |
Total Current Assets | 446.86 | 498.56 | 309.8 | 150.87 | 31.27 |
Property, Plant & Equipment | 11.07 | 12.89 | 4.97 | 4 | 0.34 |
Long-Term Deferred Charges | - | 0.04 | - | 0.3 | - |
Other Long-Term Assets | 1.06 | 0.95 | 0.16 | 0.25 | - |
Total Assets | 458.98 | 512.43 | 314.93 | 155.42 | 31.6 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Accounts Payable | 2.8 | 4.19 | 1.95 | 2.5 | 1.45 |
Accrued Expenses | 23.16 | 12.1 | 6.08 | 5.63 | 0.21 |
Current Portion of Leases | 2.47 | 2.76 | 0.74 | 0.67 | - |
Total Current Liabilities | 28.42 | 19.05 | 8.77 | 8.8 | 1.66 |
Long-Term Debt | - | - | - | 4.2 | 10.44 |
Long-Term Leases | 7.63 | 8.73 | 0.74 | 1.48 | - |
Total Liabilities | 36.06 | 27.78 | 9.51 | 14.48 | 12.1 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Common Stock | 0.05 | 0.05 | 0.04 | 0 | 0.03 |
Additional Paid-In Capital | 735.85 | 719.29 | 429.66 | 19.8 | 0.56 |
Retained Earnings | -311.7 | -235.23 | -123.75 | -45.44 | -10.65 |
Comprehensive Income & Other | -1.27 | 0.55 | -0.52 | 0 | - |
Total Common Equity | 422.93 | 484.65 | 305.43 | -25.63 | -10.06 |
Shareholders' Equity | 422.93 | 484.65 | 305.43 | 140.94 | 19.51 |
Total Liabilities & Equity | 458.98 | 512.43 | 314.93 | 155.42 | 31.6 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Total Debt | 10.11 | 11.48 | 1.48 | 6.35 | 10.44 |
Net Cash (Debt) | 425.97 | 479.06 | 303.8 | 141.13 | 20.72 |
Net Cash Growth | 71.36% | 57.69% | 115.26% | 581.01% | - |
Net Cash Per Share | 9.48 | 12.30 | 14.65 | 93.73 | 26.66 |
Filing Date Shares Outstanding | 47.98 | 47.79 | 36.5 | 4.17 | 0.78 |
Total Common Shares Outstanding | 47.96 | 47.77 | 36.58 | 4.17 | 0.78 |
Working Capital | 418.43 | 479.51 | 301.04 | 142.07 | 29.61 |
Book Value Per Share | 8.82 | 10.15 | 8.35 | -6.15 | -12.95 |
Tangible Book Value | 422.93 | 484.65 | 305.43 | -25.63 | -10.06 |
Tangible Book Value Per Share | 8.82 | 10.15 | 8.35 | -6.15 | -12.95 |
Machinery | 4.18 | 4.55 | 3.78 | 1.76 | 0.3 |
Construction In Progress | - | 0.12 | 0.43 | 0.03 | 0.06 |
Leasehold Improvements | 0.3 | 0.3 | 0.28 | 0.26 | - |